Newron Pharmaceuticals S.p.A.
Biopharmaceutical company developing therapies for nervous system disorders and pain.
NWRN | SW
Overview
Corporate Details
- ISIN(s):
- IT0004147952
- LEI:
- 8156002F8C11F80A9740
- Country:
- Italy
- Address:
- VIA MEUCCI, 3, 20091 BRESSO
- Website:
- https://www.newron.com/
- Sector:
- Manufacturing
Description
Newron Pharmaceuticals is a biopharmaceutical company focused on the research and development of novel therapies for diseases of the central and peripheral nervous system (CNS) and pain. The company's portfolio includes Xadago® (safinamide), a globally partnered treatment for Parkinson's disease. Its clinical-stage pipeline is centered on CNS disorders, with a key candidate, evenamide, under investigation for the treatment of schizophrenia.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-03-28 02:00 |
EQS-News: Newron präsentiert auf dem 31. Europäischen Psychiatrie-Kongress Sech…
|
German | 14.5 KB | ||
| 2023-03-20 01:00 |
EQS-News: Newron reports compelling topline results from all patients in Study …
|
English | 17.4 KB | ||
| 2023-03-20 01:00 |
EQS-News: Newron gibt beeindruckende Topline-Ergebnisse von allen Patienten der…
|
German | 20.6 KB | ||
| 2023-03-20 01:00 |
EQS-Adhoc: Newron gibt positive Topline-Ergebnisse von allen Patienten d…
|
German | 16.0 KB | ||
| 2023-03-17 01:00 |
EQS-News: Newron to present at the 31st European Congress of Psychiatry
|
English | 9.0 KB | ||
| 2023-03-17 01:00 |
EQS-News: Newron stellt Schizophrenie-Daten auf dem 31. Europäischen Psychiatri…
|
German | 10.7 KB | ||
| 2023-03-14 01:00 |
EQS-News: Newron announces 2022 financial results and provides outlook for 2023
|
English | 26.4 KB | ||
| 2023-03-14 01:00 |
EQS-News: Newron gibt Geschäftsergebnisse 2022 und Ausblick 2023 bekannt
|
German | 30.6 KB | ||
| 2023-03-14 01:00 |
EQS-Adhoc: Newron gibt Geschäftsergebnisse 2022 und Ausblick 2023 bekannt
|
German | 15.0 KB | ||
| 2023-02-16 01:00 |
EQS-Adhoc: Newron gibt beeindruckende Zwischenergebnisse der klinischen Phase-I…
|
German | 18.4 KB | ||
| 2023-02-16 01:00 |
EQS-News: Newron reports striking one-year interim efficacy results from its Ph…
|
English | 19.0 KB | ||
| 2023-02-16 01:00 |
EQS-News: Newron gibt beeindruckende Zwischenergebnisse der klinischen Phase-II…
|
German | 22.2 KB | ||
| 2023-01-03 01:00 |
EQS-News: Newron announces striking six-month interim results from its explorat…
|
English | 17.7 KB | ||
| 2023-01-03 01:00 |
EQS-News: Newron gibt eindrucksvolle Sechs-Monats-Zwischenergebnisse der klinis…
|
German | 20.8 KB | ||
| 2023-01-03 01:00 |
EQS-Adhoc: Newron gibt eindrucksvolle Sechs-Monats-Zwischenergebnisse der klini…
|
German | 17.6 KB |
Automate Your Workflow. Get a real-time feed of all Newron Pharmaceuticals S.p.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Newron Pharmaceuticals S.p.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Newron Pharmaceuticals S.p.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
